PMID- 29199697
OWN - NLM
STAT- MEDLINE
DCOM- 20180710
LR  - 20181202
IS  - 1998-4774 (Electronic)
IS  - 0019-509X (Linking)
VI  - 54
IP  - 1
DP  - 2017 Jan-Mar
TI  - Anaplastic lymphoma kinase status in lung cancers: An immunohistochemistry and 
      fluorescence in situ hybridization study from a tertiary cancer center in India.
PG  - 231-235
LID - 10.4103/0019-509X.219533 [doi]
AB  - BACKGROUND AND OBJECTIVES: Fluorescence in situ hybridization (FISH) and 
      immunohistochemistry (IHC) have shown good concordance for the detection of 
      echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase 
      (ALK) rearrangement. Since studies reporting FISH/IHC concordance, 
      clinicopathological features, and clinical outcomes of ALK-positive patients from 
      India are lacking, this study was undertaken. MATERIALS AND METHODS: This is a 
      retrospective, observational study of patients with adenocarcinoma of the lung on 
      whom ALK test was performed between March 2013 and December 2015. ALK status was 
      assessed in 341 patients by FISH using Vysis ALK Dual Color Break Apart 
      Rearrangement Probe and IHC using ALK D5F3 clone. Clinicopathological features 
      were noted. Patients were managed as per the standard guidelines. Clinical 
      outcomes - response rate (RR) and progression-free survival (PFS) - were 
      measured. RESULTS: ALK rearrangement was positive in 37 patients (10.9%). ALK 
      positivity was observed more commonly in younger patients with no predilection 
      for any gender or any specific histological subtype. ALK by IHC was highly 
      sensitive (100%), compared to FISH with concordance rate of 94.4%. Thirty one of 
      thirty seven (31 of 37) patients received therapy of which 3 patients received 
      palliative chemotherapy and 28 patients received tyrosine kinase inhibitors 
      (crizotinib/ceritinib). Overall RR observed was 77.4%, and median PFS had not 
      been reached at a median follow-up of 12.5 months. INTERPRETATION AND 
      CONCLUSIONS: We report higher frequency of ALK positivity (10.9%) in patients 
      with adenocarcinoma of the lung. ALK by IHC is more sensitive than FISH for ALK 
      detection with high concordance. These patients had good clinical outcome with 
      TKIs targeting ALK fusion protein.
FAU - Murthy, S S
AU  - Murthy SS
AD  - Department of Pathology and Laboratory Medicine, Basavatarakam Indo American 
      Cancer Hospital and Research Institute, Hyderabad, Telangana, India.
FAU - Rajappa, S J
AU  - Rajappa SJ
AD  - Department of Medical Oncology, Basavatarakam Indo American Cancer Hospital and 
      Research Institute, Hyderabad, Telangana, India.
FAU - Gundimeda, S D
AU  - Gundimeda SD
AD  - Department of Pathology and Laboratory Medicine, Basavatarakam Indo American 
      Cancer Hospital and Research Institute, Hyderabad, Telangana, India.
FAU - Mallavarapu, K M
AU  - Mallavarapu KM
AD  - Department of Medical Oncology, Basavatarakam Indo American Cancer Hospital and 
      Research Institute, Hyderabad, Telangana, India.
FAU - Ayyagari, S
AU  - Ayyagari S
AD  - Department of Medical Oncology, Basavatarakam Indo American Cancer Hospital and 
      Research Institute, Hyderabad, Telangana, India.
FAU - Yalavarthi, P
AU  - Yalavarthi P
AD  - Department of Medical Oncology, Basavatarakam Indo American Cancer Hospital and 
      Research Institute, Hyderabad, Telangana, India.
FAU - Fonseca, D
AU  - Fonseca D
AD  - Department of Pathology and Laboratory Medicine, Basavatarakam Indo American 
      Cancer Hospital and Research Institute, Hyderabad, Telangana, India.
FAU - Paliwal, P
AU  - Paliwal P
AD  - Department of Medical Oncology, Basavatarakam Indo American Cancer Hospital and 
      Research Institute, Hyderabad, Telangana, India.
FAU - Nair, Hgr
AU  - Nair H
AD  - Department of Pathology and Laboratory Medicine, Basavatarakam Indo American 
      Cancer Hospital and Research Institute, Hyderabad, Telangana, India.
FAU - Koppula, V
AU  - Koppula V
AD  - Department of Radiology, Basavatarakam Indo American Cancer Hospital and Research 
      Institute, Hyderabad, Telangana, India.
FAU - Raju, Kvvn
AU  - Raju K
AD  - Department of Surgical Oncology, Basavatarakam Indo American Cancer Hospital and 
      Research Institute, Hyderabad, Telangana, India.
FAU - Rao, S T
AU  - Rao ST
AD  - Department of Surgical Oncology, Basavatarakam Indo American Cancer Hospital and 
      Research Institute, Hyderabad, Telangana, India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Cancer
JT  - Indian journal of cancer
JID - 0112040
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anaplastic Lymphoma Kinase
MH  - Disease-Free Survival
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/*genetics
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - India/epidemiology
MH  - Lung Neoplasms/epidemiology/*genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - Receptor Protein-Tyrosine Kinases/*genetics
MH  - Tertiary Care Centers
EDAT- 2017/12/05 06:00
MHDA- 2018/07/11 06:00
CRDT- 2017/12/05 06:00
PHST- 2017/12/05 06:00 [entrez]
PHST- 2017/12/05 06:00 [pubmed]
PHST- 2018/07/11 06:00 [medline]
AID - IndianJournalofCancer_2017_54_1_231_219533 [pii]
AID - 10.4103/0019-509X.219533 [doi]
PST - ppublish
SO  - Indian J Cancer. 2017 Jan-Mar;54(1):231-235. doi: 10.4103/0019-509X.219533.